2157 — Lepu Biopharma Co Share Price
Last trade - 00:00- HK$7.53bn
- HK$7.73bn
- CNY225.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.44 | ||
| Price to Tang. Book | 14.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 33.16 | ||
| EV to EBITDA | 190.61 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.21% | ||
| Return on Equity | -8.66% | ||
| Operating Margin | -29.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | 15.57 | 225.35 | 278.8 | 269.38 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 19th, 2018
- Public Since
- February 23rd, 2022
- No. of Employees
- 491
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,710,614,838
- Address
- No. 651, Lianheng Road, Minhang District, SHANGHAI, 201114
- Web
- https://www.lepubiopharma.com/
- Phone
- +86 2167696099
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 2157
Similar to 2157
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:45 UTC, shares in Lepu Biopharma Co are trading at HK$4.40. This share price information is delayed by 15 minutes.
Shares in Lepu Biopharma Co last closed at HK$4.40 and the price had moved by +6.54% over the past 365 days. In terms of relative price strength the Lepu Biopharma Co share price has underperformed the FTSE Developed Asia Pacific Index by -9.85% over the past year.
The overall consensus recommendation for Lepu Biopharma Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLepu Biopharma Co does not currently pay a dividend.
Lepu Biopharma Co does not currently pay a dividend.
Lepu Biopharma Co does not currently pay a dividend.
To buy shares in Lepu Biopharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$4.40, shares in Lepu Biopharma Co had a market capitalisation of HK$7.53bn.
Here are the trading details for Lepu Biopharma Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2157
Based on an overall assessment of its quality, value and momentum Lepu Biopharma Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lepu Biopharma Co is HK$5.01. That is 13.8% above the last closing price of HK$4.40.
Analysts covering Lepu Biopharma Co currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.16 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lepu Biopharma Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +12.6%.
As of the last closing price of HK$4.40, shares in Lepu Biopharma Co were trading +20.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lepu Biopharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$4.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Lepu Biopharma Co's directors